Carryover from year -09 for Phase II Evaluation of EMD 12194

-09 年结转用于 EMD 12194 第二阶段评估

• 批准号: 7680672
• 负责人: KENNETH J. PIENTA
• 金额: $ 5.92万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-21 至 2013-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7680672
• 关键词: Androgens; Aspirate substance; Biology; Bone Marrow; Bone remodeling; Cancer Etiology; Categories; Cessation of life; Clinic; Clinical; Disease; Distant; Dose; EMD 121974 (Cilengitide); Evaluation; Goals; Hormones; Integrins; Life; Malignant Neoplasms; Malignant neoplasm of prostate; Measurable Disease; Measures; Microarray Analysis; Morbidity - disease rate; Patients; Phase; Prostate; Prostate-Specific Antigen; Quality of life; Rate; Refractory; Role; Safety; Staging; Standards of Weights and Measures; Symptoms; Systemic Therapy; Taxane Compound; Therapeutic; Toxic effect; United States; androgen independent prostate cancer; base; burden of illness; cDNA Arrays; chemotherapy; deprivation; drug development; genetic profiling; mortality; neoplastic cell; novel strategies; peripheral blood; response; stem; taxane

Prostate cancer is the second leading cause of cancer death in the United States. The primary cause of mortality is distant metastatic disease for which androgen deprivation is the initial therapeutic standard. However, virtually all patients treated with androgen deprivation will progress in a predictable and irreversible manner to androgen independence and hormone refractory state. The wide spread use of PSA in the clinic has altered the profile of patients with hormone-refractory prostate cancer. The spectrum now encompasses patients with marked differences in disease burden and symptoms with three main categories of patients that can be identified: Non- metastatic androgen independent disease with rising PSA (i.e. PSA-only disease), rising PSA with stable metastatic disease, and increasing PSA with objective progression. Although historically the role of systemic therapy has been palliative in this stage of the disease, progress in drug development has led to investigating the impact of chemotherapy on survival. Even though it is likely that taxane-based chemotherapy may have an impact on survival, the effect nonetheless is not optimal in that it is complicated by toxicities and has doubtful curative potential. As with any metastatic cancer, the ultimate goals of therapy in this setting are clear: to prolong life, to decrease morbidity, and to increase quality of life. Therefore it is particularly important to investigate alternative novel approaches that stem from observation on the biology of the disease

前列腺癌是美国癌症死亡的第二大原因。的主要原因 死亡率是以雄激素剥夺为初始治疗标准的远处转移性疾病。 然而，几乎所有接受雄激素剥夺治疗的患者都将以可预测和不可逆的方式进展。 雄激素依赖性和激素抵抗状态的方式。 PSA在临床上的广泛应用改变了难治性前列腺疾病患者的特征 癌现在，该谱包括疾病负担和症状有显著差异的患者 主要有三种类型的患者：非转移性雄激素非依赖性疾病 PSA升高（即仅PSA疾病），PSA升高伴稳定转移性疾病，PSA升高伴 客观进步。虽然从历史上看，全身治疗的作用在这个阶段是姑息性的， 疾病，药物开发的进展导致调查化疗对生存的影响。甚至 尽管紫杉烷类化疗可能对生存率有影响，但其效果仍然是 不是最佳的，因为它被毒性所复杂化，并且具有可疑的治疗潜力。与任何转移性 癌症，在这种情况下治疗的最终目标是明确的：延长生命，降低发病率， 提高生活质量。因此，研究替代的新方法是特别重要的， 源于对疾病生物学的观察